Stem Cells, Inc. Expanding Trial in Age-Related Eye Affliction – Xconomy
|
Stem Cells, Inc. Expanding Trial in Age-Related Eye Affliction
Xconomy Taking another tack, companies such as Newark, CA-based Stem Cells, Inc. (NASDAQ: STEM) are injecting preparations of live cells into the eyes of clinical trial participants with the dry version of the disorder. The hope is that these stem cells will … |
